Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 317

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 317
---
. Mireskandari joined DiamiR in July 2022, and has over 12 years of life sciences industry experience with
a focus on molecular diagnostic test development and commercialization, including regulatory and reimbursement expertise. Dr. Mireskandari
most recently served as Chief Development Officer of Interpace Biosciences from 2013 to 2022, and prior to that as President & CEO
of JS Genetics from 2009 to 2013. From 2000 to 2009, Dr. Mireskandari was a hedge fund manager in charge of Life Sciences trading portfolios
of Nomura Securities, BNP Paribas and Raeburn Advisors. Prior to this experience, he was a consultant with PRTM’s life sciences
industry group from 1998 to 2000 and a research fellow at National Institutes of Health’s National Cancer Institute from 1990 to
1996. Dr. Mireskandari holds his Ph.D. in Generics from George Washington University and his MBA from the University of Michigan Ross
School of Business.

Kira S. Sheinerman, Ph.D., MBA, Treasurer and Secretary, Executive Director.Kira Sheinerman joined DiamiR in September 2009, and is
DiamiR’s Co-Founder and Executive Director. Dr. Sheinerman was also Executive Chairman of DiamiR, LLC prior to and after the
Share Exchange. Since November 2015, Dr. Sheinerman has served as a Managing Director, Healthcare Investment Banking at H.C.
Wainwright & Co., LLC, where she works on financial and strategic transactions for growth life sciences companies. Previously,
she was a Managing Director of Healthcare Investment Banking at Burrill & Company from 2012 to 2013 and Rodman & Renshaw
from 2005 to 2012. Prior to investment banking, Dr. Sheinerman worked at the Arcus group, a life sciences strategic consulting firm.
From 2010 to 2021 she served as a board member of the Boyce Thompson Institute, an affiliate of Cornell University; from 2015
through 2018 she served as the co-chair of Alzheimer’s Association Business Consortium; and from 2020 to 2023 she served as
the senior strategic consultant to Aptorum Group (NASDAQ: APM). In 2008-2009, Dr. Sheinerman chaired the Board Executive Committee
of Xenomics (now Cardiff Oncology